XML 53 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income
The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2022202120222021
Segment Net Sales    
United States$786.8 $753.3 $2,337.1 $2,223.7 
Europe291.9 268.9 901.8 806.1 
Japan130.9 126.2 416.9 384.6 
Rest of World160.9 136.1 449.1 393.6 
Total segment net sales$1,370.5 $1,284.5 $4,104.9 $3,808.0 
Segment Operating Income    
United States$535.0 $527.4 $1,596.0 $1,544.1 
Europe156.0 140.6 487.1 426.5 
Japan87.3 83.7 282.7 258.3 
Rest of World63.7 49.5 178.0 145.2 
Total segment operating income$842.0 $801.2 $2,543.8 $2,374.1 
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated pre-tax income (in millions):
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2022202120222021
Net Sales Reconciliation    
Segment net sales$1,370.5 $1,284.5 $4,104.9 $3,808.0 
Foreign currency(51.5)25.7 (70.8)94.8 
Consolidated net sales$1,319.0 $1,310.2 $4,034.1 $3,902.8 
Pre-tax Income Reconciliation    
Segment operating income$842.0 $801.2 $2,543.8 $2,374.1 
Unallocated amounts:    
Corporate items(415.6)(413.6)(1,285.4)(1,178.7)
Special charge (Note 3)(66.8)— (66.8)— 
Intellectual property litigation income (expenses), net2.4 (4.7)(10.8)(13.5)
Change in fair value of contingent consideration liabilities, net12.5 (1.1)36.3 106.0 
Foreign currency27.9 8.5 83.6 28.0 
Consolidated operating income402.4 390.3 1,300.7 1,315.9 
Non-operating (expense) income 4.9 0.6 7.4 9.8 
Consolidated pre-tax income$407.3 $390.9 $1,308.1 $1,325.7 
Schedule of Enterprise-Wide Information
The following enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2022202120222021
Net Sales by Geographic Area    
United States$786.8 $753.2 $2,337.1 $2,223.6 
Europe270.1 291.1 884.0 880.9 
Japan104.1 125.9 362.5 390.0 
Rest of World158.0 140.0 450.5 408.3 
$1,319.0 $1,310.2 $4,034.1 $3,902.8 
Net Sales by Major Product Area    
Transcatheter Aortic Valve Replacement$862.3 $857.8 $2,650.5 $2,551.0 
Transcatheter Mitral and Tricuspid Therapies29.7 22.3 84.6 60.7 
Surgical Structural Heart219.7 217.4 669.0 667.8 
Critical Care207.3 212.7 630.0 623.3 
$1,319.0 $1,310.2 $4,034.1 $3,902.8